Literature DB >> 21995295

DrugPred: a structure-based approach to predict protein druggability developed using an extensive nonredundant data set.

Agata Krasowski1, Daniel Muthas, Aurijit Sarkar, Stefan Schmitt, Ruth Brenk.   

Abstract

Judging if a protein is able to bind orally available molecules with high affinity, i.e. if a protein is druggable, is an important step in target assessment. In order to derive a structure-based method to predict protein druggability, a comprehensive, nonredundant data set containing crystal structures of 71 druggable and 44 less druggable proteins was compiled by literature search and data mining. This data set was subsequently used to train a structure-based druggability predictor (DrugPred) using partial least-squares projection to latent structures discriminant analysis (PLS-DA). DrugPred performed well in discriminating druggable from less druggable binding sites for both internal and external predictions. The method is robust against conformational changes in the binding site and outperforms previously published methods. The superior performance of DrugPred is likely due to the size and composition of the training set which, in contrast to most previously developed methods, only contains cavities that have evolved to bind a natural ligand.

Mesh:

Substances:

Year:  2011        PMID: 21995295     DOI: 10.1021/ci200266d

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  22 in total

1.  Elucidating the druggability of the human proteome with eFindSite.

Authors:  Omar Kana; Michal Brylinski
Journal:  J Comput Aided Mol Des       Date:  2019-03-19       Impact factor: 3.686

Review 2.  Pocket-based drug design: exploring pocket space.

Authors:  Xiliang Zheng; Linfeng Gan; Erkang Wang; Jin Wang
Journal:  AAPS J       Date:  2012-11-22       Impact factor: 4.009

3.  PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database.

Authors:  Xia Wang; Yihang Shen; Shiwei Wang; Shiliang Li; Weilin Zhang; Xiaofeng Liu; Luhua Lai; Jianfeng Pei; Honglin Li
Journal:  Nucleic Acids Res       Date:  2017-07-03       Impact factor: 16.971

4.  Mitigating cold-start problems in drug-target affinity prediction with interaction knowledge transferring.

Authors:  Tri Minh Nguyen; Thin Nguyen; Truyen Tran
Journal:  Brief Bioinform       Date:  2022-07-18       Impact factor: 13.994

5.  Scaling the druggability landscape of human bromodomains, a new class of drug targets.

Authors:  Guangtao Zhang; Roberto Sanchez; Ming-Ming Zhou
Journal:  J Med Chem       Date:  2012-08-28       Impact factor: 7.446

6.  New Frontiers in Druggability.

Authors:  Dima Kozakov; David R Hall; Raeanne L Napoleon; Christine Yueh; Adrian Whitty; Sandor Vajda
Journal:  J Med Chem       Date:  2015-08-11       Impact factor: 7.446

7.  The AEROPATH project targeting Pseudomonas aeruginosa: crystallographic studies for assessment of potential targets in early-stage drug discovery.

Authors:  Lucille Moynie; Robert Schnell; Stephen A McMahon; Tatyana Sandalova; Wassila Abdelli Boulkerou; Jason W Schmidberger; Magnus Alphey; Cyprian Cukier; Fraser Duthie; Jolanta Kopec; Huanting Liu; Agata Jacewicz; William N Hunter; James H Naismith; Gunter Schneider
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-12-25

8.  Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites.

Authors:  Lewis R Vidler; Nathan Brown; Stefan Knapp; Swen Hoelder
Journal:  J Med Chem       Date:  2012-07-12       Impact factor: 7.446

9.  CAVIAR: a method for automatic cavity detection, description and decomposition into subcavities.

Authors:  Jean-Rémy Marchand; Bernard Pirard; Peter Ertl; Finton Sirockin
Journal:  J Comput Aided Mol Des       Date:  2021-05-29       Impact factor: 3.686

10.  Large-scale reverse docking profiles and their applications.

Authors:  Minho Lee; Dongsup Kim
Journal:  BMC Bioinformatics       Date:  2012-12-13       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.